[¹⁸F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer

Prostate cancer (PCa) is the most common malignant tumor in men in Western countries and, until recently, the metastatic disease has been considered as a unique clinical entity requiring up-front systemic therapy, either hormonal or chemotherapy [1, 2].

In the last years, functional imaging has given a significant contribution to clinical decision-making of biochemical relapsed PCa, allowing early diagnosis of metastatic disease [3, 4]. The extensive use of functional imaging resulted in the identification of a new clinical disease entity called oligometastatic disease and characterized by a limited tumor burden [5, 6]. Consequently, the paradigm of metastatic PCa has evolved and, nowadays, tumor burden is a crucial parameter that must be considered in the treatment planning of selected patients [5, 7‐11]. Several experiences have even shown that by treating with local ablative approaches, such as stereotactic body radiotherapy (SBRT), all the lesions revealed by functional imaging, a PSA fall can be achieved [5, 7, 8]. Moreover, the demonstration of PSA control with repeated SBRT has led several authors to investigate the administration of systemic therapy only in case of PSA failure due to diffuse disease, a condition not suitable for SBRT. However, currently, most of the studies evaluating SBRT in oligometastatic disease have a retrospective design and are characterized by a pure radiotherapy focus.

Hereby, we present a prospective study aiming to validate the role of [¹⁸F]Fluoro-Methyl Choline ([¹⁸F]FMCH) PET/CT in the selection of PCa patients suitable for SBRT.

Fifty-one patients were included in the present study. Forty-six patients with oligometastatic PCa (castration sensitive in 35 patients, castration-resistant in 11) for a total of 67 lesions (lymph node and bone lesions, in 45 and 22 cases, respectively) were considered evaluable for the present analysis. Among the 44 patients who underwent radical prostatectomy, pT2 and pT3 stages were recorded in 11 and 33 patients, respectively; 11 of these patients presented even a nodal involvement.

After SBRT, five patients were lost at follow-up since they started ADT for a personal reason. Patients’ median age at the time of study entry was 70 years (range 50–81). The median length between PCa diagnosis and study enrollment was 69 months (range, 2–180 months). At the time of study entry, Median PSA value was 2.69 ng/mL (range 0.9–27.40). Table 1 shows baseline patients’ characteristics. After the first SBRT, two patients developed a failure in the prostate bed. They were both treated with salvage external beam radiotherapy and, because the achievement of PSA control, they were still considered oligometastatic and appropriate for this study.

In-field progression was observed in 3 lesions. After the detection of oligorecurrent disease following SBRT, 6 patients underwent further courses of SBRT on the active lesions revealed by [¹⁸F]FMCH-PET/CT (two, three, four, five courses respectively in 4,1,1,1 patients). Toxicity higher than grade 2 was not recorded. At data analysis, median follow-up was 28.9 months (range 4.3–88.4), and systemic therapy was started in 24 patients (65.2%). Median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6, Fig. 1) whereas systemic free survival ratios at 6, 12, and 24 month were 93.5%, 73.9%, and 63.1%, respectively. Results of univariate analyses are reported in Table 2.

To our knowledge, the present study represents one of the first prospective experiences carried out in patients with oligometastatic prostate cancer treated with SBRT. At the time of biochemical recurrence, all patients were re-staged using [¹⁸F]FMCH-PET/CT, and salvage treatment was selected based on the imaging findings. Patients with no more than 3 synchronous metastases were treated with repeated SBRT on all the detected lesions. Otherwise, systemic therapy was initiated. Since the prerequisite for a curative SBRT is an accurate patients’ selection, one of the most critical issues on oligometastatic patients with PCa is the accurate definition of the tumor burden, a critical aspect to planning local treatments [13]. In this study, we aimed to validate [¹⁸F]FMCH PET/CT as the technique of choice in selecting patients and active metastases to be treated with SBRT. The literature on this topic is failing, consisting of retrospective proof of concept studies; consequently, the importance of functional imaging in patients and target validation in oligometastatic PCa has not addressed yet. In 2013, Berkovic et al., in a retrospective analysis of 24 patients with oligometastatic PCa treated with SBRT after choline-PET/CT or [¹⁸F]FDG PET/CT assessment, reported a delay of anti-androgen therapy of 38 months and a 1-year and 2-year rate of ADT-free survival of 82% and 54%, respectively [8]. Similarly, Triggiani and Decaester obtained a median delay of anti-androgen therapy of 11 and 25 months, respectively [14, 15]. However, all these studies share the limitations of the lacking standard imaging technique, underestimating the importance of patients’ assessment before SBRT planning. A recent prospective randomized phase II trial by Ost et al. shows that metastasis-directed therapy (MDT) has advantages over surveillance in patients with up to three metastatic lesions from PCa, suggesting that MDT can be further explored in phase III trial to delay systemic therapy initiation [16]. Despite the prospective design, also in this study, the role of functional imaging in selecting patients suitable for SBRT was not deeply investigated. Indeed, we believe that the technique of patient selection would deserve a special focus, being the definition of oligometastatic state dependent on the imaging ability to detect macroscopic and microscopic disease. The emergence and widespread of whole body MRi and PSMA PET/CT have led to an increase detection of metastatic PCa, particularly at low PSA levels. [⁶⁸Ga]PSMA-11 and [¹⁸F]-Flucicovine have shown improving PCa patients’ management and outcome. [⁶⁸Ga]PSMA-11, despite not clinically approved, has outperformed standard-of-care imaging (including choline) for detecting PCa recurrence at low PSA values [17‐19]. Indeed, a recent meta-analysis revealed detection rates with [⁶⁸Ga]PSMA-11 PET/CT of 58% in patients with PSA between 0.2 and 1.0 ng/mL, 76% for PSA between 1 and 2 ng/mL and 95% for PSA > 2.0 ng/mL [20]. Nonetheless, its role in guiding radiation therapy even if promising is still to be validated [21], and very few data are available in the setting of oligometastatic disease [22, 23]. The use of [¹⁸F]Flucicovine resulted in a high positive predictive value for detecting extra prostatic disease in the setting of biochemical recurrence. However, it suffered from high false positive rates that could result in incorrectly upstaging the disease [24]. This will lead inevitably to a modification in the management of PCa. Therefore, the definition of oligometastatic disease should always be accompanied by the details of the imaging technique used for patients’ selection.

In the next future, we can foresee significant changes in the management of patients’ with recurrent PCa, as already anticipated by the inclusion in the latest EAU guideline of the use of PSMA-11 PET/CT (i) after RP if the PSA level is > 0.2 ng/mL and if the results will influence subsequent treatment decisions or (ii) after RT in patients fit for curative salvage treatment. We strongly believe that using [⁶⁸Ga]PSMA-11 might significantly improve the detection of oligometastatic/oligorecurrent disease, as also sustained by the demonstration of [⁶⁸Ga]PSMA-11 higher detection rate as compared with radiolabeled choline [25]. However, the present study was designed in the “pre [⁶⁸Ga]PSMA-11 era” (i.e., 2010) when radiolabeled choline PET/CT was accounted for the most effective procedure in PCa and comparative data on a per-patients analysis of the two radiopharmaceuticals were not available. Indeed, despite choline-based radiopharmaceuticals might appear out-of-date, they still represent an elegant combination of clinical utility (good detection rate) and feasibility (registration and high availability for PCa restaging) as confirmed by the same EAU guideline in which the use of choline PET/CT (or fluciclovine PET/CT) is still recommended in case PSMA PET/CT is not available and the PSA level is > 1 ng/mL. Most important, we believe that the strength of the current study is related to its clinical message, independent from the radiopharmaceutical, which is the ability of SBRT in patients with oligometastatic disease of postponing the use of systemic therapy. In the next future, clinical trials using [⁶⁸Ga]PSMA-11 as restaging procedure or comparing choline-based radiopharmaceuticals and [⁶⁸Ga]PSMA-11 in patients with recurrent PCa are needed to demonstrate the impact of this new imaging modality on PCa patients’ outcome. Indeed, this is currently under investigation in our Center within a phase III prospective randomized clinical trial (Phase III clinical trial Oligometastatic and Oligorecurrent Prostate Cancer: enhancing patients’ selection by new imaging biomarkers – PROvING, EudraCT number 2018-004458-14).

Similarly, the definition of oligometastatic disease is evolving by moving from a definition based on limited number or limited location of the metastasis to the identification of biomarkers to segregate which patients should undergo to local treatment, thus by identifying key features of this biologically different entity compared with high-burden metastasis disease [26]. In the current study, we decided to apply the same definition of oligometastatic disease (up to three synchronous active lesions) as well the same SBRT schedules (24 Gy as a single fraction versus 27 Gy in three fractions) we already adopted in a prospective multicenter phase III clinical trial (NCT01223248) started in 2011 in patients with different type of cancer.

In our study, all patients were prospectively selected using the combination of pelvic MRI and [¹⁸F]FMCH PET/CT. Follow-up was based on PSA assessment, and in case of PSA rise further [¹⁸F]FMCH PET/CT was performed. By treating all the active lesions in 46 patients, we obtained a systemic therapy-free survival of 39.1 months (95% CI 6.5–68.6). The corresponding 6, 12, and 24-month systemic-free survival rate was 93.5%, 73.9%, and 63.1%, respectively. We used systemic therapy-free survival defined as the length from the PET/CT used to enroll patients in this study to the onset of at least four synchronous active metastases, and then the administration of systemic therapy, as a surrogate parameter of overall survival. This choice was based on the impossibility to use overall survival after [¹⁸F]FMCH-PET/CT-guided SBRT since at this stage of the clinical trial, all patients, beside one, are still alive. However, follow-up is still ongoing, and long-term results on overall survival are under evaluation. Through our preliminary results, we have already reported successful PCa patients’ selection for subsequent SBRT using [¹⁸F]FMCH-PET/CT [5]; the present paper confirms these preliminary findings in a larger number of patients with a longer follow-up. In our study, no significant difference between hormone naïve and castration-resistant patients was found. In fact, [¹⁸F]FMCH-PET/CT was able to identify oligometastatic patients not only at first biochemical recurrence but also after hormone therapy failure. Thus, it is in line with the results reported by Triggiani et al. in a multicenter retrospective study in oligometastatic castration-resistant patients treated with SBRT who found a median systemic treatment-free survival of 21.8 months and 1-year systemic treatment-free survival of 72.1% [27].

The median PSA value at the time of [¹⁸F]FMCH PET/CT was 2.69 ng/m. Univariate analysis showed that a fall of PSA value was associated with longer systemic therapy-free survival (p < 0.001). We interpreted this result as a consequence of a higher and longer response rate to SBRT in the presence of positive [¹⁸F]FMCH PET/CT, thus detecting all the sites of active disease and not only an ice cap.

[¹⁸F]FMCH-PET/CT has been investigated in the case of biochemical recurrence for patients’ selection for locoregional treatment such as salvage lymphadenectomy. Our findings on the use of functional imaging to guide local therapy in recurrent PCa are coherent with results reported in surgical series. In 2013, Tilki et al. reported results of 56 patients with PSA relapse treated with choline PET/CT-guided lymph node dissection. They identified at last one lymphatic metastasis in 85% of patients with positive PET/CT and only 4% of false positive in patients with PSA value higher than 2 ng/ml [28]. In 2015, Winter et al. reported their experience carried out in 13 patients, a biochemical response was observed in 11 out of 13 patients after an [¹⁸F]FMCH-PET/CT-guided lymphadenectomy. The authors concluded that their results could be improved in a larger series and prospective trials [29]. Moreover, Giovacchini et al., in a series of 358 biochemical PCa recurrent patients underwent radical prostatectomy, found a sensibility of 46% and 82% in patients with PSA level between 1 and 3 ng/mL and > 3, respectively [30].

In the present experience, toxicity higher than grade 2 was not recorded, and the safety we reported was the same observed in the previous studies [8, 15, 16]. The safety of SBRT is an essential consideration in the context of oligometastatic PCa patients who present longer life expectancy as compared with the plurimetastatic patients, therefore, making possible the onset of SBRT late toxicity. Based on our findings related to the safety of SBRT, and confirmed by other authors, we can be confident on the use of SBRT in oligometastatic PCa. Also, by postponing the administration of hormonal therapy or chemotherapy, we have also avoided the onset of potential toxicity, allowing a better quality of life that, in elderly patients with many comorbidities, can even affect overall survival.

Based on our findings, [¹⁸F]FMCH PET/CT can identify oligometastatic patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.